Tiffany Wu
Nurse Practitioner · Rocklin, CANPI 1245839463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,614, 2.7 times the $605 reported in 2021. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$715
- Lilly USA, LLC$610
- GSK$555
- Johnson & Johnson$439
- Pfizer$437
- AbbVie$390
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,61299%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 27 | $715 |
| Lilly USA, LLC | 24 | $610 |
| GSK | 25 | $555 |
| Johnson & Johnson(2 entities) | 20 | $439 |
| Pfizer | 19 | $437 |
| AbbVie | 24 | $390 |
| Viiv Healthcare Company | 16 | $355 |
| Novo Nordisk | 15 | $336 |
| Novartis | 17 | $272 |
| AstraZeneca(2 entities) | 7 | $235 |
| Gilead | 7 | $147 |
| Alk-abello, Inc | 7 | $146 |
| Boehringer Ingelheim | 5 | $118 |
| Sanofi Pasteur Inc. | 4 | $82 |
| UCB, Inc. | 4 | $81 |
| Dexcom, Inc. | 2 | $63 |
| Exact Sciences | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $57 |
| Scilex Pharmaceuticals Inc. | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $54 |
| Merck | 2 | $52 |
| Cranial Technologies, Inc | 4 | $51 |
| Organon | 3 | $45 |
| Shield Therapeutics Inc | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| Bayer | 2 | $40 |
| Phadia US Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $30 |
| Hologic Sales And Service, LLC | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Qiagen, LLC | 1 | $19 |
| Abbott | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,693 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $55,169 |
| OzempicSemaglutide | 44 | $48,134 |
| TrulicityDulaglutide | 27 | $24,999 |
| RybelsusSemaglutide | 21 | $24,748 |
| EliquisApixaban | 25 | $14,802 |
| JanuviaSitagliptin Phosphate | 20 | $12,612 |
| FarxigaDapagliflozin Propanediol | 15 | $8,701 |
| MyrbetriqMirabegron | 19 | $7,778 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,469 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $3,109 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $3,073 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,365 |
| Celecoxib | 18 | $2,098 |
| Gabapentin | 122 | $1,439 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $1,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $336 | $72,88265 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $118 | $61,63872 claims |
| Lilly USA, LLCTrulicity | $610 | $24,99927 claims |
| PfizerEliquis | $437 | $14,80225 claims |
| MerckJanuvia | $52 | $12,61220 claims |
| AstraZenecaFarxiga | $235 | $8,70115 claims |
| GSKArnuity Ellipta | $555 | $2,36512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Rocklin
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.